[Gastric lyphoma - still a result of surgery?].
In extranodal non-Hodgkin's lymphoma (NHL), the gastrointestinal tract is by far the most frequent localization. One must differentiate between primary lymphoma, e.g. those arising in the gastrointestinal tract, and secondary lymphoma, which can affect the digestive tract as a disseminations of nodal lymphoma. Analysis of histomorphologic and immunhistochemical characteristics and the concept of mucosa-associated lymphoid tissue (MALT) have led to primary gastrointestinal lymphoma now being viewed as an independent entity. The great majority of gastric lymphoma (>90%) are marginal zone B-cell lymphoma of the MALT type, previously called low grade MALT lymphoma, and diffuse large B-cell lymphoma, previously called high grade gastric lymphoma. This review examines current views on pathogenesis, diagnosis, and therapy of this disorder.
Fischbach
W
W
Medizinische Klinik II, Klinikum Aschaffenburg, Lehrkrankenhaus der Universität Würzburg, Am Hasenkopf, 63739 Aschaffenburg. med2-aschaffenburg@t-online.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001706:Biopsy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D003937:Diagnosis, Differential; D004317:Doxorubicin; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016393:Lymphoma, B-Cell / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000145:classification / Q000175:diagnosis / Q000473:pathology; D009367:Neoplasm Staging; D011241:Prednisone; D011379:Prognosis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D000069283:Rituximab; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D013997:Time Factors; D014750:Vincristine; D014944:World Health Organization
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone